Friday, January 28, 2011

Dennis Lo's paper on non-invasive Down's syndrome diagnostics is finally published in the British Medical Journal

The proof of concept of the test, which will be brought to market to market by the San Diego-based company Sequenom, Inc (NASDAQ: SQNM) sometime this year showed very high accuracy in a reasonably large clinical trial. We salute Dennis Lo and Sequenom on these results and hope that the tests will be launched to general public as soon as possible.
Now that we know that the test works, Sequenom has a moral duty to the pregnant women to bring it to market as soon as possible and reduce the number of unnecessary invasive procedures and resulting spontaneous abortions and damage to the fetus.

Here is a link to the story and Sequenom's press release

Press Release Source: Sequenom, Inc. On Wednesday January 12, 2011, 2:45 pm EST

SAN DIEGO, Jan. 12, 2011 /PRNewswire/ -- Sequenom (Nasdaq:SQNM - News) is very pleased to note the publication in the British Medical Journal (BMJ 2011;342:c7401) of a groundbreaking international study led by our longstanding collaborator, Professor Dennis Lo of The Chinese University of Hong Kong. Building on early work from the Lo laboratory, the present paper is the first report of a large-scale clinical study that validates a noninvasive, plasma DNA-based approach for prenatally detecting Down's syndrome (T21). Sequenom congratulates the research team for their achievements.


About Sequenom

Sequenom, Inc. (NASDAQ:SQNM - News) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

31st meeting of the Society for Maternal-Fetal Medicine will be in San Francisco February 7-12


31st Annual Meeting
The Pregnancy MeetingTM
Date: February 7, 2011 - February 12, 2011
Location: Hilton San Francisco Union Square
333 O'Farrell St.
San Francisco, CA
Use Group Code: SFM to get the special SMFM rate. Use the link below for online reservations.
Description: The SMFM 31st Annual Meeting will present cutting-edge basic, clinical, and epidemiological research. In addition to oral and poster presentations, attendees will hear from world-renowned leaders in the specialty of maternal-fetal medicine.
Attachments: 2011 Exhibitor Prospectus

31st Annual Meeting Preliminary Program
Click on the link above to download a PDF of the meeting brochure.

2011 Poster Instructions
Please click on the link above to download a PDF of the 2011 SMFM poster presentation instructions.
2011 Scientific Forum Agendas
Click on the link above to download a PDF file of the 2011 Scientific Forum Agendas.
AJOG SMFM Manuscript Submission Instructions
Please click on the link above to down load a PDF of the AJOG SMFM Manuscript Submission Guidelines.
Exhibit Floor Plan
Please click on the link above to download the 2011 exhibit floor plan. For more information on 2011 Exhibits, please click here.
On-site Registration form
Please click on the link above to download the on-site meeting registration form.

Shocking truth revealed by testing the pregnant women in the US

An article published at Science Daily reveals shocking news:

99% of Pregnant Women in US Test Positive for Multiple Chemicals Including Banned Ones, Study Suggests

nalyzing data for 163 chemicals, researchers detected polychlorinated biphenyls (PCBs), organochlorine pesticides, perfluorinated compounds (PFCs), phenols, polybrominated diphenyl ethers (PBDEs), phthalates, polycyclic aromatic hydrocarbons (PAHs) and perchlorate in 99 to 100 percent of pregnant women. Among the chemicals found in the study group were PBDEs, compounds used as flame retardants now banned in many states including California, and dichlorodiphenyltrichloroethane ( DDT), an organochlorine pesticide banned in the United States in 1972.

Bisphenol A (BPA), which makes plastic hard and clear, and is found in epoxy resins that are used to line the inside of metal food and beverage cans, was identified in 96 percent of the women surveyed. Prenatal exposure to BPA has been linked to adverse health outcomes, affecting brain development and increasing susceptibility to cancer later in life, according to the researchers.

Findings will be published in Environmental Health Perspectives on Jan. 14.